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Prealbumin and mortality 7-84 PTH or aluminum
antagonism in the resistance
To the Editor: In a 1998 paper that included an exami-
nation of the association of prealbumin and mortality in of uremic bone to the
hemodialysis [1], Owens and Lowrie reported that pre-
albumin was “not significantly associated with the odds remodeling effect of
risk of death after adjustment for the other variables,”
including albumin. This statement appears to contradict endogenous PTH?a new study about prealbumin published in the Decem-
ber 2000 issue of Kidney International [2], in which Lowrie
and colleagues “confirmed” that inclusion of prealbumin To the Editor: To accept the explanation of Slatopol-
in a Cox model of mortality “extinguished the signifi- sky et al [1] that the antagonism of 7-84 parathyroid hor-
cance of serum albumin” as a mortality predictor. The mone (PTH) versus 1-84 PTH could explain the propen-
authors may wish to clarify this discrepancy. sity of dialysis patients to develop adynamic bone disease
Second, the authors of the new study seem to have (ABD), it would be necessary to document a lower pro-
incorrectly attributed the use of a binary cutoff for pre- portion of non–1-84 PTH measured by the Nichols PTH
albumin (#30 vs. .30 mg/dL) to a 1993 paper written immunoradiometric assay (IRMA) in transplanted pa-
by me and my colleagues [3]. In fact, we explored four tients than in dialysis patients. Therefore, we wonder
different levels of prealbumin, overlapping the range why the contrary is reported by the authors since this
examined in the new study, and we found a relative risk proportion is 44% in transplanted patients and 34% in
of 4.5 (95% CI, 1.6 to 13.8) associated with prealbumin dialysis patients.
,15 mg/dL, not very different from the relative risk of It would be also logical to expect that patients with
2.6 for prealbumin ,20 mg/dL reported in the new study. ABD would have a higher proportion of non–1-84 PTH
The proposal using 30 mg/dL as a cut-off originated than those with osteitis fibrosa. However John et al re-
earlier with Cano et al [4]. ported that this proportion is actually slightly lower in
Finally, I would like to emphasize that since the albu- two patients with ABD (52 and 55%) than in six patients
min bromcresol green dye assay is probably subject to with osteitis fibrosa (61 to 59%) [2].
more interference than the immunoassay for prealbu- Previous exposure of dialysis patients to aluminum
min, perhaps this measurement “noise” accounts for part phosphate binders may play a more critical role in de-
of the decreased significance of albumin compared to pre- termining the increase of intact PTH range necessary to
albumin as a mortality predictor in most studies [2–4]. prevent ABD. Indeed, for Quarles et al, Nichols’ PTH
levels should be maintained between 1.5 and 2.5, the
Philip Goldwasser upper limit of normal, whereas for Wang et al they shouldBrooklyn, New York, USA
be higher (2 to 4 times) [3]. However, the aluminum
Correspondence to Philip Goldwasser, M.D., Brooklyn VA Medical overload was greater in Wang’s patients. In our patients
Center, 111-F, 800 Poly Place, Brooklyn, NY 11209, USA. who had never been exposed to aluminum phosphate
binders (unlike those of Quarles et al) osteitis fibrosis
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